| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 02/01/2011 | CA2125472C A method for generation of antibodies to cell surface molecules |
| 01/27/2011 | WO2011011706A2 Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents |
| 01/27/2011 | WO2011011384A2 Synthesis of dendrimer conjugates |
| 01/27/2011 | WO2011011231A1 3-phenoxymethylpyrrolidine compounds |
| 01/27/2011 | WO2011011092A1 Methods and compositions to reduce oxidative stress |
| 01/27/2011 | WO2011010678A1 Polyphenol-containing composition for oral administration or external use and use of same |
| 01/27/2011 | WO2011010456A1 EXTERNAL PREPARATION CONTAINING NSAIDs AND METHOD FOR PRODUCING THE EXTERNAL PREPARATION |
| 01/27/2011 | WO2010140139A3 Crystalline forms of 6-(1h- imadazol- 1-yl) -2-phenylquinazoline |
| 01/27/2011 | WO2010134100A3 Method for extraction of fractions containing pharmacologically active ingredients with less cytotoxicity from one or more plants |
| 01/27/2011 | WO2010099445A3 Non-covalent inhibition of the 26s proteasome and uses thereof |
| 01/27/2011 | US20110021974 Retinitis pigmentosa treatment and prophalaxis |
| 01/27/2011 | US20110021747 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
| 01/27/2011 | US20110021628 CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG |
| 01/27/2011 | US20110021617 Medicinal Acidic Cannabinoids |
| 01/27/2011 | US20110021597 3-phenoxymethylpyrrolidine compounds |
| 01/27/2011 | US20110021593 Novel crystal of substituted phenylalkanoic acid ester and process for producing the same |
| 01/27/2011 | US20110021590 Aminopyrrolidinone derivatives and uses thereof |
| 01/27/2011 | US20110021588 Sublingual dexmeditomidine compositions and methods of use thereof |
| 01/27/2011 | US20110021586 Phenyl-sulfamates as aromatase inhibitors |
| 01/27/2011 | US20110021582 Benzophenone thiazole derivatives useful for inhibiting formation of microtubule and method for producing the same |
| 01/27/2011 | US20110021577 Aryloxy amine compounds and their use as sodium channel modulators |
| 01/27/2011 | US20110021559 Aminopyridines useful as inhibitors of protein kinases |
| 01/27/2011 | US20110021558 Thieno-pyridine derivatives as mek inhibitors |
| 01/27/2011 | US20110021548 Inhibitors of malt1 proteolytic activity and uses thereof |
| 01/27/2011 | US20110021540 Bis-(Sulfonylamino) Derivatives in Therapy 066 |
| 01/27/2011 | US20110021534 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease |
| 01/27/2011 | US20110021525 P70S6 Kinase Modulators and Method of Use |
| 01/27/2011 | US20110021523 Aryl sulfonamides |
| 01/27/2011 | US20110021521 Fused heterocyclic compounds as ion channel modulators |
| 01/27/2011 | US20110021514 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| 01/27/2011 | US20110021513 Modulators of interleukin-1 receptor-associated kinase |
| 01/27/2011 | US20110021505 Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain |
| 01/27/2011 | US20110021501 Substituted piperazino-dihydrothienopyrimidines |
| 01/27/2011 | US20110021500 Novel compounds |
| 01/27/2011 | US20110021499 Urethral suppositories for overactive bladder |
| 01/27/2011 | US20110021497 Amino triazoles as pi3k inhibitors |
| 01/27/2011 | US20110021495 Quinazoles useful as modulators of ion channels |
| 01/27/2011 | US20110021494 Novel tetrahydro-fused pyridines as histone deacetylase inhibitors |
| 01/27/2011 | US20110021491 Compounds, pharmaceutical composition and methods relating thereto |
| 01/27/2011 | US20110021473 Inhibitors of phosphodiesterase type-iv |
| 01/27/2011 | US20110021457 Pharmaceutical compositions comprising modified fucans and methods relating thereto |
| 01/27/2011 | US20110021449 Macrolides and uses of macrolides |
| 01/27/2011 | US20110021448 Inhibitors for the Soluble Epoxide Hydrolase |
| 01/27/2011 | US20110021443 OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES |
| 01/27/2011 | US20110021438 Novel compounds of the n-acylamino-amide family, compositions comprising them and uses thereof |
| 01/27/2011 | US20110021437 Method for reducing pain with ziconotide and baclofen |
| 01/27/2011 | US20110021436 Method for reducing pain with ziconotide and morphine |
| 01/27/2011 | US20110021425 Tricyclic inhibitors of jak |
| 01/27/2011 | US20110021419 Methods and Compositions for the Treatment of Heart Failure and Other Disorders |
| 01/27/2011 | US20110021413 Methods of suppressing microglial activation |
| 01/27/2011 | US20110020870 Methods for producing modified glycoproteins |
| 01/27/2011 | US20110020480 Use of benzoxazinoids-containing cereal grain products for health-improving purposes |
| 01/27/2011 | US20110020465 Methods of treatment of gout using thymus-derived compositions |
| 01/27/2011 | US20110020464 Methods of treatment using thymus-derived compositions |
| 01/27/2011 | US20110020437 Oligopeptidic compounds and uses thereof |
| 01/27/2011 | US20110020436 Topical application of melatonin directly or in liposomes for the amelioration of itching and histamine and non-histamine related inflammatory skin changes |
| 01/27/2011 | US20110020424 Use of the irritating principal oleocanthal in olive oil, as well as structurally and functionally similar compounds |
| 01/27/2011 | US20110020400 Probiotic bifidobacterium strains |
| 01/27/2011 | US20110020392 Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers |
| 01/27/2011 | US20110020377 Aminopyrimidines useful as inhibitors of protein kinases |
| 01/27/2011 | US20110020369 Engineered anti-tslpr antibodies |
| 01/27/2011 | US20110020363 Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13ralpha1) |
| 01/27/2011 | US20110020349 Anti-factor xi monoclonal antibodies and methods of use thereof |
| 01/27/2011 | US20110020338 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes |
| 01/27/2011 | US20110020328 Antibody formulations |
| 01/27/2011 | US20110020321 Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 01/27/2011 | US20110020318 Inhibitors of the Interaction Between HMGB Polypeptides and Toll-Like Receptor 2 as Anti-Inflammatory Agents |
| 01/27/2011 | US20110020316 Composition and method to alleviate joint pain |
| 01/27/2011 | US20110020315 Treatment of inflammatory illnesses with ace2 |
| 01/27/2011 | US20110020311 Therapy of multiple sclerosis, inflammatory neurological diseases and neurodegenerative diseases with 5'-deoxyadenosylcobalamin, growth hormone, immunomodulators, interleukins, other therapeutic agents, and physiotherapy |
| 01/27/2011 | US20110020309 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergice disease |
| 01/27/2011 | US20110020303 Novel use of probiotics |
| 01/27/2011 | US20110020293 Use of Stem Cells to Reduce Leukocyte Extravasation |
| 01/27/2011 | US20110020284 Probiotic bifidobacterium strains |
| 01/27/2011 | US20110020271 Elastin for soft tissue augmentation |
| 01/27/2011 | US20110020264 Method and Composition for the Treatment of Scars |
| 01/27/2011 | US20110020250 Personal-care composition comprising a hydrocarbon wax and a polar oil |
| 01/27/2011 | US20110020227 Polysaccharide-containing block copolmer particles and uses thereof |
| 01/27/2011 | DE102010027315A1 Verfahren zur Entwicklung einer als Schaum auf die Haut zu applizierende flüssige Zusammensetzung sowie eine topisch applizierbare Zusammensetzung A process for the development of a foam on the skin as a liquid composition to be applied, and a topically applicable composition |
| 01/27/2011 | DE102009027938A1 Oral dosage form, useful to administer active agent to human/animal and treat organism or its (patho)physiological conditions, comprises a base body with an opening, where the body contains an active agent formulation and blowing agent |
| 01/26/2011 | EP2278004A1 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| 01/26/2011 | EP2277920A2 Inhibitors of complement activation |
| 01/26/2011 | EP2277881A1 Heterocyclic compound having inhibitory activity on p13k |
| 01/26/2011 | EP2277880A1 Macrolides with VEGF transcription suppression activity |
| 01/26/2011 | EP2277876A1 Substituted pyrimidines for the treatment of cancer |
| 01/26/2011 | EP2277865A1 Phenyl-substituted 6-ring nitrogen-heterocycles as microtubule polymerisation inhibitors |
| 01/26/2011 | EP2277861A1 Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same |
| 01/26/2011 | EP2277850A1 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists |
| 01/26/2011 | EP2277848A1 Indene derivatives as pharmaceutical agents |
| 01/26/2011 | EP2277526A1 Pharmaceutical composition with tetrahydroisohumulone |
| 01/26/2011 | EP2276774A2 Therapeutic substances that modulate genome methylation |
| 01/26/2011 | EP2276773A2 Compounds with glycidic structure active in the therapy of systemic and local inflammation |
| 01/26/2011 | EP2276765A1 Salinosporamide derivatives as proteasome inhibitors |
| 01/26/2011 | EP2276738A1 Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors |
| 01/26/2011 | EP2276737A1 4- [3- (aryloxy) benzylidene]-3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors |
| 01/26/2011 | EP2276736A1 4- [3- (aryloxy) benzyliden]-3-methyl piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors |
| 01/26/2011 | EP2276735A1 Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors |
| 01/26/2011 | EP2276734A1 4-benzylidene-3-methylpiperidine aryl carboxamide compounds useful as faah inhibitors |
| 01/26/2011 | EP2276477A2 Self-destructing transdermal therapeutic system having improved functionality and efficacy |
| 01/26/2011 | EP2276469A2 Alpha adrenergic receptor agonists for treatment of degenerative disc disease |